<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03306277</url>
  </required_header>
  <id_info>
    <org_study_id>AVXS-101-CL-303</org_study_id>
    <nct_id>NCT03306277</nct_id>
  </id_info>
  <brief_title>Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1</brief_title>
  <acronym>STR1VE</acronym>
  <official_title>Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AveXis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AveXis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3 pivotal US trial studying open-label intravenous administration of AVXS-101 in SMA
      Type 1 patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3, open-label, single-arm, single-dose, study of AVXS-101 (gene replacement therapy) in
      patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are
      genetically defined by nonfunctional survival motor neuron 1 gene (SMN1) with 1 or 2 copies
      of survival motor neuron 2 gene (SMN2). Fifteen (15) patients &lt; 6 months (&lt; 180 days) of age
      at the time of gene replacement therapy (Day 1) will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>one-time intravenous administration of AVXS-101</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of independent sitting</measure>
    <time_frame>18 months of age visit</time_frame>
    <description>Achievement of developmental milestone of independent sitting at 18 months of age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>14 months of age visit</time_frame>
    <description>Event-free survival at 14 months of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability to thrive</measure>
    <time_frame>Through 18 months of age</time_frame>
    <description>Determine effect of AVXS-101 on the ability to thrive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilatory support independence</measure>
    <time_frame>Through 18 months of age</time_frame>
    <description>Determine the effect of AVXS-101 on the ability to remain independent of ventilatory support</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>SMA - Spinal Muscular Atrophy</condition>
  <condition>Gene Therapy</condition>
  <arm_group>
    <arm_group_label>AVXS-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one-time Intravenous administration of AVXS-101 at the therapeutic dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVXS-101</intervention_name>
    <description>Non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.</description>
    <arm_group_label>AVXS-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with SMA Type 1 based on gene mutation analysis with bi-allelic SMN1
             mutations (deletion or point mutations) and 1 or 2 copies of SMN2 (inclusive of the
             known SMN2 gene modifier mutation (c.859G&gt;C))

          -  Patients must be &lt; 6 months (&lt; 180 days) of age at the time of AVXS-101 infusion

          -  Patients must have a swallowing evaluation test performed prior to administration of
             gene replacement therapy

        Exclusion Criteria:

          -  Tracheostomy or current use or requirement of non-invasive ventilatory support
             averaging ≥ 6 hours daily over the 7 days prior to the screening visit; or ≥ 6
             hours/day on average during the screening period or requiring ventilatory support
             while awake over the 7 days prior to screening or at any point during the screening
             period prior to dosing

          -  Patients with signs of aspiration/inability to tolerate non-thickened liquids based on
             a formal swallowing test performed as part of screening. Patients with a gastrostomy
             tube who pass the swallowing test will be allowed to enroll in the study

          -  Patients whose weight-for-age is below the third percentile based on World Health
             Organization (WHO) Child Growth Standards

          -  Participation in recent SMA treatment clinical study (with the exception of
             observational cohort studies or non-interventional studies) or receipt of an
             investigational or commercial compound, product, or therapy administered with the
             intent to treat SMA (e.g., nusinersen, valproic acid) at any time prior to screening
             for this study. Oral β-agonists must be discontinued at least 30 days before gene
             therapy dosing. Inhaled albuterol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>180 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AveXis Medical Information</last_name>
    <phone>833-828-3947</phone>
    <email>medinfo@avexis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Sam</last_name>
      <phone>310-825-3264</phone>
      <email>chsam@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Perry Shieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Paulose</last_name>
      <phone>650-724-3792</phone>
      <email>spaulose@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carolyn McLaughlin Savage</last_name>
      <email>cjmclaug@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Johnson</last_name>
      <phone>720-777-3293</phone>
      <email>Hannah.Johnson@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Lauri Filar</last_name>
      <phone>720-777-5173</phone>
      <email>Lauri.Filar@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Parsons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Berry</last_name>
      <phone>407-650-7523</phone>
      <email>Debbie.Berry@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Richard Finkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Munson</last_name>
      <phone>312-227-2201</phone>
      <email>HMunson@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Nancy Kuntz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Pediatric Neurology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes King Rennie</last_name>
      <phone>443-287-6294</phone>
      <email>aking2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Tom Crawford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Ordonez</last_name>
      <phone>617-355-7384</phone>
      <email>Grace.Ordonez@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jenna Dauriac</last_name>
      <phone>617-355-2752</phone>
      <email>Jennifer.Dauriac@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Basil Darras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Unviersity School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pallavi Anand</last_name>
      <phone>314-362-2490</phone>
      <email>anandp@neuro.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ann Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shumaila Saad</last_name>
      <phone>212-305-2461</phone>
      <email>ss3967@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Berry</last_name>
      <phone>212-342-3038</phone>
      <email>kb2996@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Claudia Chiriboga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christie Milleson</last_name>
      <phone>919-684-2687</phone>
      <email>christie.milleson@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Loren Pena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryn McCarthy</last_name>
      <phone>503-418-8297</phone>
      <email>mccarbry@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Erica Finanger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josh Zigmont</last_name>
      <phone>267-426-7161</phone>
      <email>zigmontj@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diane Barcoski</last_name>
      <phone>267-425-0158</phone>
      <email>barcoskid@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gihan Tennekoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Ramm</last_name>
      <phone>214-456-4426</phone>
      <email>Tammy.Ramm@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Iannaccone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Janecki</last_name>
      <phone>801-581-3724</phone>
      <email>teresaj@genetics.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin (Madison)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connstance Trantow</last_name>
      <phone>608-265-7814</phone>
      <email>cbt@clinicaltrials.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Meredith Schultz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://studysmanow.com</url>
    <description>Recruitment Website</description>
  </link>
  <link>
    <url>http://AveXis.com</url>
    <description>sponsor company website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2017</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

